Clinical TrialMajor Depressive Disorder (MDD)Completed

Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State

This phenomenological exploration trial (n=15) aims to investigate the transient dissociative state induced by esketamine in patients with depressive disorder.

Target Enrollment
15 participants
Study Type
Phase NA interventional
Design
Non-randomized

Detailed Description

This single‑group, basic‑science study uses an experiential phenomenological interview and the EQFC "Trait" questionnaire to explore the contents and structure of the transient dissociative state following routine esketamine treatment in patients with depressive disorder.

Participants are identified during routine esketamine sessions at the psychiatry department; consenting patients who experienced a transient dissociative state 2 days to 3 months after treatment undergo a recorded 45‑minute interview and questionnaire in a separate research consultation.

Findings will clarify the phenomenology of esketamine‑induced dissociation and inform therapeutic strategies to manage anxiety associated with dissociative experiences that may affect antidepressant response.

Study Arms & Interventions

Depressive patients

experimental

Patients with depressive disorder treated with esketamine 2 days–3 months prior to study.

Interventions

  • Compound
    via Other• single session• 1 doses total

    Experiential Phenomenological Interview (audio-recorded) and completion of EQFC "Trait" questionnaire; research consultation ~45 minutes.

Participants

Ages
18 – 99
Sexes
Male & Female

Inclusion Criteria

  • Patient followed in the Psychiatry Department of Hôpital Sainte Musse, with depressive state characterised by DSM‑V criteria and treated with Esketamine between 2 days and 3 months prior to the study;
  • Patient over the age of 18;
  • Patient presented transient dissociative state during Esketamine treatment;
  • Patient able to express his/her consent prior to participation in the study;
  • Patient who understands and speaks French.

Exclusion Criteria

  • Patient with major anxiety and panic attack during an Esketamine‑induced dissociative state, regardless of Esketamine effect;
  • Patient under judicial protection (guardianship, curatorship...) or safeguard of justice;
  • Pregnant, parturient or breast‑feeding women;
  • Any other reason that, in the opinion of the investigator, would interfere with the evaluation of the study objectives.

Study Details

  • Status
    Completed
  • Phase
    Phase NA
  • Type
    interventional
  • Design
    Non-randomized
  • Target Enrollment15 participants
  • Timeline
    Start: 2023-12-01
    End: 2024-09-01
  • Topic
    Major Depressive Disorder (MDD)

Locations

Centre Hospitalier Intercommunal Toulon La Seyne sur Mer — Toulon, Var, France

Your Library